Description
Enzyme immunoassay for the quantitative determination of Fibroblast growth factor-23 (FGF-23) in human EDTA plasma samples. Quality controls are included with the kit. Developed and manufactured in Europe by PromedeusLab.
Summary
Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone involved in mineral bone metabolism that helps control phosphate homeostasis and reduces 1,25- dihydroxyvitamin D synthesis. Recent data have highlighted the relevant direct FGF-23 effects on the myocardium, and high plasma levels of FGF-23 have been associated with adverse cardiovascular outcomes in humans, such as heart failure and arrhythmias. Therefore, FGF23 has emerged as a novel biomarker of cardiovascular risk. experimental data suggest FGF-23 as a direct mediator of cardiac hypertrophy development, cardiac fibrosis and cardiac dysfunction via specific myocardial FGF receptor (FGFR) activation (1).
Other Names
Fibroblast growth factor 23 (FGF23), Phosphatonin, Tumor-derived hypophosphatemia-inducing factor, HYPF, UniProtKB# Q9GZV9.
Principle of Method
The microtiter plate is coated with the antibody specifically binding Fibroblast growth factor 23. The human EDTA plasma is incubated in the plate with the capture antibody.
The specimen is washed out and the specifically bound protein is incubated with biotin-labelled detection antibody. Following another washing step, Streptavidin-HRP conjugate is added into the well. Unbound reagent is then washed out. Horseradish peroxidase (HRP) bound in the complex reacts with the chromogenic substrate (TMB) creating the blue colour. The reaction is stopped by addition of STOP solution (H2SO4).
The absorbance values are measured at 450 nm (optionally 450/630 nm) and are proportional to the concentration of FGF23 in the specimen. The concentration of FGF23 in unknown samples is determined from the calibration curve which is created by plotting the absorbance values against the standard concentration values.
Sample Types
EDTA Plasma
Typical Standard Curve
Assay Range: 50 pg/mL - 2000 pg/mL
Sensitivity
The limit of detection, defined as a concentration of human FGF23 giving absorbance higher than absorbance of blank + 3 standard deviations, is better than 12.5 pg/mL of sample.
Precision
Intra-Assay
| Test sample | Mean (pg/mL) | SD | CV |
| 1 |
1718 |
100 |
5.8% |
| 2 |
492 |
19 |
3.8% |
Inter-Assay (Run-to-Run)
| Test sample | Mean (pg/mL) | SD | CV |
| 1 |
41 |
3 |
6.3% |
| 2 |
742 |
90 |
12.1% |
Accuracy
Dilution Linearity:
| Test sample | Dilution |
Measured Concentration (pg/mL) |
Expected Concentration (pg/mL) |
Yield |
| 1 |
2003 |
- | - | |
| 1 | 2x | 1058 |
1001 |
106% |
| 1 | 4x | 544 |
501 |
109% |
| 1 | 8x | 284 |
250 |
113% |
| 2 |
441 |
- |
- | |
| 2 | 2x | 231 |
221 |
105% |
| 2 | 4x | 111 |
110 |
101% |
| 2 | 8x | 61 |
55 |
110% |
Spiking Recovery:
| Test sample | Spike (ng/mL) |
Measured Concentration (pg/mL) |
Expected Concentration (pg/mL) |
Yield |
| 1 |
- | 61 |
- | - |
| 1 | 800 |
749 |
861 |
87% |
| 1 | 400 |
421 |
461 |
91% |
| 1 | 200 |
225 |
261 |
86% |
Storage
The kit must be stored at 2–8 °C. The opened components can be stored for one week at 2–8 °C.
Usage
This assay is for in vitro research use only and is not for use in diagnostic procedures.
Resources
Summary References
- Vázquez-Sánchez S, Poveda J, Navarro-García JA, González-Lafuente L, Rodríguez-Sánchez E, Ruilope LM, Ruiz-Hurtado G. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Front Physiol. 2021 Mar 9;12:632260. doi: 10.3389/fphys.2021.632260. PMID: 33767635; PMCID: PMC7985069.
Related Products
Ilex Life Sciences LLC is an authorized distributor of PromedeusLab.